comparemela.com

Latest Breaking News On - Arbutu president - Page 1 : comparemela.com

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed. | May 4, 2023

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting

01.11.2022 - HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced . Seite 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.